Rivastigmine, a New‐Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease
Tóm tắt
Rivastigmine is a cholinesterase inhibitor (ChEI) with a structural formula different from that of currently available ChEIs. Tacrine and donepezil are classified as short‐acting or reversible agents since binding to acetylcholinesterase enzyme (AChE) is hydrolyzed within minutes. Rivastigmine is classified as an intermediate‐acting or pseudo‐irreversible agent due to its long inhibition on AChE of up to 10 hours. Preclinical biochemical studies indicated that rivastigmine has central nervous system selectivity over peripheral inhibition. It ameliorated memory impairment in rats with forebrain lesions. The drug is rapidly absorbed orally, with a bioavailability of 0.355 and low protein binding (40%). Its elimination half‐life is less than 2 hours, and it is converted to an inactive metabolite at the site of action, bypassing hepatic metabolic pathways. Its disposition essentially is unaltered in patients with renal or hepatic impairment. It also has dose‐dependent effects on AChE inhibition. In the two large multicenter clinical trials (total 1324 patients) that used a forced‐dosage titration scheme, rivastigmine 6–12 mg/day was superior to placebo on three cognitive and functioning scales (p<0.001). Gastrointestinal symptoms are the most frequently reported adverse events. They occurred mostly during the dosage titration phase and decreased during the maintenance phase. Rivastigmine offers clinicians another therapeutic agent to treat Alzheimer's disease.
Từ khóa
Tài liệu tham khảo
Jann MW, 1998, PSAP, 27
Small GW, 1997, Diagnosis and treatment of Alzheimer's disease and related disorders, JAMA, 278, 1363
Jann MW, 1998, Preclinical pharmacology of metrifonate, Pharmacotherapy, 18, 55S, 10.1002/j.1875-9114.1998.tb03879.x
Anand R., 1996, Clinical development of Exelon (ENA 713): the ADENA programme, J Drug Dev Clin Pract, 8, 9
Enz A., 1994, Alzheimer's disease. Therapeutic strategies, 211
Weinstock M., 1997, Possible role of the cholinergic system and disease models, J Neural Transm, 49, 93
Weinstock M., 1994, Pharmacologic evaluation of phenyl‐carbamates as CNS selective acetylcholinesterase inhibitors, J Neural Transm, 43, 219
Anand R., 1996, Efficacy and safety results of the early phase studies with Exelon (ENA 713) in Alzheimer's disease: an overview, J Drug Dev Clin Pract, 8, 1
Games D., 1997, Alzheimer‐type neuropathology in transgenic mice overexpressing V71F β‐amyloid precursor protein, Nature, 336, 523
Tanaka K., 1993, Effects of the acetylcholinesterase inhibitor ENA‐713 on ischemia‐induced changes in acetylcholine and aromatic amine levels in the gerbil brain, Arch Int Pharmacodyn, 323, 85
Schran HF, 1996, The effects of renal and hepatic impairment on the disposition of the acetylcholinesterase inhibitor SDZ ENA 713, Pharm Res, 13, S‐428
DeJong R., 1989, Measurement of quality‐of‐life changes in patients with Alzheimer's disease, Clin Ther, 11, 545
Cutler NR, 1996, Alzheimer's disease. Therapeutic strategies, 387
Corey‐Bloom J., 1998, A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderate severe Alzheimer's disease, Int J Geriatr Psychopharmacol, 1, 55
Cutler NR, 1998, Antiemetic therapy for Alzheimer's patients receiving the cholinesterase inhibitor SDZ ENA 713, Clin Pharmacol Ther, 63, 188
Steele CD, 1999, Recognition and management of early Alzheimer's disease, J Clin Outcomes Manage, 6, 52
Crismon ML, 1998, Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer disease, Pharmacotherapy, 18, 47S, 10.1002/j.1875-9114.1998.tb03878.x